Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2026 | Standardizing neurodegenerative disease biomarkers for clinical reliability

Chiara Giangrande, PhD, Laboratoire National de Métrologie et d’Essais, Paris, France, presents the NeuroBioStand Initiative, a European consortium focused on standardizing biomarkers for neurodegenerative diseases through metrology. The project aims to establish reference measurement procedures and certified materials for biomarkers including phospho-tau217, neurofilament light, and GFAP, improving test comparability and reliability across platforms to enhance clinical accuracy and patient trust. This interview took place at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

NeuroBioStand is a European consortium that has been funded under the European Partnership of Metrology. And the main objective is the standardization of biomarkers for neurodegenerative diseases by using metrology. And metrology is the science of measurement, so it’s important to put together clinicians, academics, and the National Metrology Institute to meet these objectives. So we are working on the establishment of SI traceability for three biomarkers in particular, so for phospho-tau and we are targeting phospho-tau 217 in particular, NFL and GFAP...

NeuroBioStand is a European consortium that has been funded under the European Partnership of Metrology. And the main objective is the standardization of biomarkers for neurodegenerative diseases by using metrology. And metrology is the science of measurement, so it’s important to put together clinicians, academics, and the National Metrology Institute to meet these objectives. So we are working on the establishment of SI traceability for three biomarkers in particular, so for phospho-tau and we are targeting phospho-tau 217 in particular, NFL and GFAP. So we are developing reference measurement procedures and certified reference materials for these three biomarkers and this will be the main objective of this work. At the end of this project, but probably we will continue in the future after the end of this project, we will produce these certified reference materials that will be available for the community so either manufacturers can establish traceability of their calibration materials to our materials and what is important is that this will enhance the comparability of the available tests that are now on the market and this will help patients to have more accurate tests and this will also help patients to develop their trust in these tests.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...